BAGSVAERD, Denmark, April 23, 2014 (GLOBE NEWSWIRE) -- At Novo Nordisk's Annual General Meeting on 20 March 2014, it was decided to reduce the company's B share capital from DKK 442,512,800 to DKK 422,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 20,000,000 divided into 100,000,000 B shares of DKK 0.20 each.

Further information

Media:    
Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com
     
Investors:    
Kasper Roseeuw Poulsen +45 3079 4303krop@novonordisk.com
Frank Daniel Mersebach +45 3079 0604fdni@novonordisk.com
Lars Borup Jacobsen +45 3075 3479lbpj@novonordisk.com
Daniel Bohsen +45 3079 6376dabo@novonordisk.com
Jannick Lindegaard (US) +1 609 235 8567jlis@novonordisk.com

Company announcement No 25 / 2014

Reduction of the share capital http://hugin.info/2013/R/1779113/607762.pdf

HUG#1779113